Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han, Shenghao Tu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	rheumatic diseases immune-related adverse events immune checkpoint inhibitors arthritis myositis vasculitis Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b7c2204f3119464d8aab962e1985c5bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7c2204f3119464d8aab962e1985c5bc
record_format	dspace
spelling	oai:doaj.org-article:b7c2204f3119464d8aab962e1985c5bc2021-11-04T06:16:59ZRheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy2296-858X10.3389/fmed.2021.762247https://doaj.org/article/b7c2204f3119464d8aab962e1985c5bc2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fmed.2021.762247/fullhttps://doaj.org/toc/2296-858XImmune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of inflammation in off-target organs and autoimmunity resulting from non-specific immune activation. These irAEs can cause rheumatic diseases and manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca and Sjogen's syndrome, and systemic lupus erythematosus. Early diagnosis and treatment of these adverse events will improve outcomes and quality of life for cancer patients. The treatment of rheumatic diseases induced by ICIs requires multidisciplinary cooperation among physicians. Furthermore, the underlying mechanisms are not fully understood and it is difficult to predict and evaluate these side effects precisely. In this review, we summarize available studies and findings about rheumatic irAEs, focusing mainly on the clinical manifestations, epidemiology, possible mechanisms, and guiding principles for treating these irAEs.Pan ShenXuan DengZhishuo HuZhe ChenYao HuangKe WangKai QinYing HuangXin BaJiahui YanLiang HanShenghao TuFrontiers Media S.A.articlerheumatic diseasesimmune-related adverse eventsimmune checkpoint inhibitorsarthritismyositisvasculitisMedicine (General)R5-920ENFrontiers in Medicine, Vol 8 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	rheumatic diseases immune-related adverse events immune checkpoint inhibitors arthritis myositis vasculitis Medicine (General) R5-920
spellingShingle	rheumatic diseases immune-related adverse events immune checkpoint inhibitors arthritis myositis vasculitis Medicine (General) R5-920 Pan Shen Xuan Deng Zhishuo Hu Zhe Chen Yao Huang Ke Wang Kai Qin Ying Huang Xin Ba Jiahui Yan Liang Han Shenghao Tu Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
description	Immune checkpoint inhibitors (ICIs), which can enhance antitumor immunity and inhibit cancer growth, have revolutionized the treatment of multiple cancers and dramatically decreased mortality. However, treatment with ICIs is directly associated with immune-related adverse events (irAEs) because of inflammation in off-target organs and autoimmunity resulting from non-specific immune activation. These irAEs can cause rheumatic diseases and manifestations such as inflammatory arthritis, polymyalgia rheumatica, myositis, vasculitis, Sicca and Sjogen's syndrome, and systemic lupus erythematosus. Early diagnosis and treatment of these adverse events will improve outcomes and quality of life for cancer patients. The treatment of rheumatic diseases induced by ICIs requires multidisciplinary cooperation among physicians. Furthermore, the underlying mechanisms are not fully understood and it is difficult to predict and evaluate these side effects precisely. In this review, we summarize available studies and findings about rheumatic irAEs, focusing mainly on the clinical manifestations, epidemiology, possible mechanisms, and guiding principles for treating these irAEs.
format	article
author	Pan Shen Xuan Deng Zhishuo Hu Zhe Chen Yao Huang Ke Wang Kai Qin Ying Huang Xin Ba Jiahui Yan Liang Han Shenghao Tu
author_facet	Pan Shen Xuan Deng Zhishuo Hu Zhe Chen Yao Huang Ke Wang Kai Qin Ying Huang Xin Ba Jiahui Yan Liang Han Shenghao Tu
author_sort	Pan Shen
title	Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_short	Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_full	Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_fullStr	Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_full_unstemmed	Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy
title_sort	rheumatic manifestations and diseases from immune checkpoint inhibitors in cancer immunotherapy
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/b7c2204f3119464d8aab962e1985c5bc
work_keys_str_mv	AT panshen rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT xuandeng rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT zhishuohu rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT zhechen rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT yaohuang rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT kewang rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT kaiqin rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT yinghuang rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT xinba rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT jiahuiyan rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT lianghan rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy AT shenghaotu rheumaticmanifestationsanddiseasesfromimmunecheckpointinhibitorsincancerimmunotherapy
_version_	1718445111901159424

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

Ejemplares similares